About: Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
QLGN NASDAQ Qualigen Therapeutics Inc
Qualigen Therapeutics Inc share price
Atividade de preço de QLGN
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
QLGN price performance
quote.marketSignals